Home / Posts of the author gilles

Auteur/autrice : gilles

Invectys’ CARGo project: $14.2M 2020 CPRIT Award

Invectys well poised to bring its anti-HLA-G CAR-T cells to clinical trials …

Read more

Invectys : Dennis J. Purcell (Aisling Capital) join Adv...

Invectys Strengthens Advisory Board with the Appointment of Dennis J. Purcell, Life Sciences Industry Veteran and Founder of Aisling Capital LLC Paris, France, May…

Read more

Invectys publishes positive clinical results for its IN...

Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research   With an extended Phase I and a new delivery method…

Read more

Mission and vision

Invectys focuses on the development of innovative anti-cancer therapeutic approaches in immunotherapy. It is backed by French and international private investors…

Read more

Invectys élu meilleur projet 2019 par le Board de MATWIN

Invectys élu « meilleur projet – jeune entreprise » 2019 par le Board international de MATWIN Invectys, société biopharmaceutique développant des thérapies…

Read more

BIO€QUITY Europe, Paris May 22, 23

Invectys will attend to the 18th annual BIO€QUITY Europe Meet Invectys there ! More information:  invest@invectys.com 18TH ANNUAL BIO€QUITY EUROPE Bio€quity…

Read more

Invectys AT BIO-Europe Spring 2019, Vienna March 25th 2...

BIO-Europe Spring 2019 March 25th – 27th 2019 Messe Wien Exhibition and Congress Center, Vienna, Austria Invectys will be attending the BIO-Europe Spring 2019.…

Read more

INVAC-1 : A DNA vaccine targeting cancer

A DNA vaccine targeting a specific cancer marker Cancer cells produce an enzyme which is key to their unlimited proliferation, but is nearly never expressed in normal…

Read more